Matheus Barros de Albuquerque

Matheus Barros de Albuquerque

Auto-generated profile, based on publicly available information

Matheus Barros de Albuquerque

Division of Medicine Federal University of Pernambuco Recife Pernambuco Brazil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2024 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
MAMatheus Barros de Albuquerque
Matheus Barros de Albuquerque
LNLuiz Eduardo Duarte Borges Nunes
Luiz Eduardo Duarte Borges Nunes
JMJoão Victor de Oliveira Maldonado
João Victor de Oliveira Maldonado
DFDiogo Grassano Melo Ferreira
Diogo Grassano Melo Ferreira
MMMateus Macedo Margato
Mateus Macedo Margato
LCLúcia Helena Oliveira Cordeiro
Lúcia Helena Oliveira Cordeiro

27 March 2026 in Experimental Dermatology
Verified
Journal Article
Open access
RMRafaela de Moraes‐Souza
Rafaela de Moraes‐Souza
MBMaria Júlia Pilau Bornia
Maria Júlia Pilau Bornia
RCRegina Chahine Chater
Regina Chahine Chater
Francesco PiscazziFrancesco Piscazzi
Francesco Piscazzi
MAMatheus Barros de Albuquerque
Matheus Barros de Albuquerque
PHPedro Herranz‐Pinto
Pedro Herranz‐Pinto
Chronic hand eczema (CHE) is associated with substantial functional impairment and reduced quality of life. Delgocitinib, a pan‐Janus kinase (JAK) inhibitor, has emerged as a promising topical treatment for CHE. A systematic review and meta‐analysis of randomized controlled trials (RCTs) was conducted to assess the efficacy and safety of topical delgocitinib 20–30 mg/g compared with vehicle in patients with CHE. PubMed, Embase, Cochrane Library, ClinicalTrials.gov , EU CTR, and WHO ICTRP were searched up to 15 February 2026. The primary outcome was treatment success at week 16, defined as clear or almost clear skin with a ≥ 2‐point improvement on the Investigator's or Physician's Global Assessment (IGA/PGA). Secondary outcomes included treatment success at weeks 4 and 8, changes in Hand Eczema Symptom Diary (HESD) itch and pain scores, and safety outcomes. Relative risks (RRs) and mean differences (MDs) with 95% confidence intervals (CIs) were calculated using random‐effects models. Three publications reporting four RCTs involving 1154 patients were included, with 752 receiving delgocitinib and 402 receiving vehicle. At week 16, treatment success was significantly higher with delgocitinib (RR 3.17; 95% CI 1.78–5.65; p < 0.01), corresponding to an absolute risk difference of 16.9% and a number needed to treat (NNT) of 6 (95% CI 3–16). Similar results at weeks 4 and 8. Delgocitinib also led to significantly greater improvements in HESD itch and pain scores. No significant differences were found in overall adverse events (AEs), treatment‐related AEs, or serious AEs. Discontinuation due to AEs was lower in the delgocitinib group. Delgocitinib 20–30 mg/g demonstrated greater efficacy than vehicle and a favourable safety profile, supporting its use as a topical treatment for CHE.

1 September 2023 in Cuadernos de Educación y Desarrollo
Verified
Journal Article
Open access
PDF file
TLTarciana Maria Pereira De Lima
Tarciana Maria Pereira De Lima
JRJoão Gabriel de Lima Raulinho
João Gabriel de Lima Raulinho
MAMatheus Barros De Albuquerque
Matheus Barros De Albuquerque
MAMaria de Fatima Viana Vasco Aragao
Maria de Fatima Viana Vasco Aragao
BCBelmira Lara da Silveira Andrade Da Costa
Belmira Lara da Silveira Andrade Da Costa
Covid-19 is a viral disease, caused by SARS-CoV-2, with a cyclical epidemiological behavior, causing systemic complications, mainly in the neurological field. In these cases, the patient needs to be evaluated clinically and by complementary exams, such as brain computed tomography (CT) and magnetic resonance imaging (MRI). In the last years, efforts have been made in order to clarify molecular mechanisms involved in this disease. Several studies have demonstrated the importance and variety of neuroimaging findings, most of which point to alterations related to hemorrhagic, inflammatory and prothrombotic events, bringing an increased risk of death. The aim of this review was to gather the recent evidence by imaging approach on the neurological early and long term risks especially those involved with unfavorable clinical damage, presence of comorbidities and invasive procedures. The present data indicates that Infection with SARS-CoV-2 brought a diversity of neurological changes in adults and the elderly, with long-term effects on the cognition. However, special interest and investigation needs to be given to the neonatal and pediatric cases, due to the inherent risks of the disease, development of systemic inflammatory syndromes and reported deaths.

2 January 2024 in Contribuciones A Las Ciencias Sociales
Verified
Journal Article
Open access
PDF file
TLTarciana Maria Pereira De Lima
Tarciana Maria Pereira De Lima
JRJoão Gabriel de Lima Raulinho
João Gabriel de Lima Raulinho
MAMatheus Barros de Albuquerque
Matheus Barros de Albuquerque
MAMaria de Fatima Viana Vasco Aragao
Maria de Fatima Viana Vasco Aragao
BCBelmira Lara da Silveira Andrade Da Costa
Belmira Lara da Silveira Andrade Da Costa
A COVID-19 é uma doença viral, com variável sintomatologia de acordo com as variantes virais e vacinação. O início da pandemia gerou mudanças comportamentais e na realidade da saúde de crianças e adolescentes, no aspecto biológico, isolamento social e psicossocial. Avaliar as complicações da infecção pelo SARS-CoV-2 no público pediátrico, propondo uma atuação multidisciplinar de tratamento e prevenção. O presente estudo trata-se de uma revisão integrativa, realizado a partir de buscas nas bases de dados da SCIELO, BVS e PubMed, utilizando os descritores: “COVID-19”, “Pediatria” e “Complicações”, entre os anos de 2022 e 2023. Foram encontrados 19 artigos, 3 descartados. A maior parte relatou as consequências biológicas agudas da infecção pelo novo coronavírus. Os estudos direcionam uma mudança na investigação das consequências da pandemia, no âmbito psicológico e social. A COVID-19 gerou condições inflamatórias multissistêmicas, na sua maioria, principalmente no grupo com comorbidades, por isso foi incentivada a vacinação, para controle da transmissão e prevenção das sequelas. O estresse, o medo da doença e o isolamento social, repercutiram no desenvolvimento, comprometeram o tratamento de doenças prévias e contribuíram para os transtornos no âmbito psicossocial.